abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
9620: Nuclear Matrix Proteins (NMP) Print View
NMP22 Bladder Tumor Marker EIA  < 10.1  U/mL 

PRIMARY
1 Urine Additive 10 (5) mL   Room Temperature - 4 Day(s)/Frozen - 56 Day(s)/Refrigerated - 7 Day(s)  
ALTERNATE

NMP22 is involved in DNA replication. NMP22 is increased in patients with bladder carcinomas. NMP22 appears to be more sensitive and specific for low grade bladder cancers than urine cytology alone.

Collect a single void of urine between midnight and noon. Stabilize
sample immediately. Stabilized urine collected with the NMP22
Urine Collection Kit should be blue/green in color.
Keep sample away from direct sunlight.
1. Test should not be performed on persons with total cystectomy.
2. Urine sample should be collected at least 5 days after invasive
procedures such as cystoscopy or catherization.
Setup Schedule
Wednesday

Reported (Analytical Time)
Same day

CPT Code
86316

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
NMP22, urine test for bladder cancer, is now approved for use as an aid in diagnosing patients at high risk for bladder cancer. The following table summarizes the diagnostic sensitivity of the NMP22 test compared to cytology, in patients with various stages and types of bladder cancer. The sensitivity of NMP22 versus Bladder Cytology Tumor Size(mm) NMP22(%) Bladder Wash Cytology (%) ---------------------------------------------------- <=10 76 32 11-20 67 37 21-30 75 36 >=31 93 85 Tumor Grade --------------------------------------------------- 1 73 8 2 72 43 3 81 77 Tumor Stage --------------------------------------------------- Ta 69 23 T1 81 64 T2 or greater 91 73 Adapted from: Boman H, Hedelin H, Jacobsson S Holmang S. Newly Diagnosed Bladder Cancer: The Relationship of initial Symptoms, Degree of Microhematuria and Tumor Marker Status. J Urol 168: 1955-1959, 2002. This test is performed on the Matritech NMP-22 Test Kit, which is an enzyme immunoassay (EIA) for the in vitro quantitative determination of the nuclear matrix protein NMP22 in stabilized voided urine. Values obtained with different assay methods or kits cannot be used inter-changeably. The NMP22 result should not be interpreted as evidence of the presence or absence of malignant disease in the urinary tract without corroboration from other diagnostic procedures and should only be used in conjunction with other diagnostic information in the management of patients with transitional cell carcinoma of the urinary tract.






1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database